Biotechnology · Healthcare
Board Member
2022-01-01–present
Board Member
Processa Pharmaceuticals, Inc. (PCSA)Equibles does not estimate personal net worth.
Get an email with a short summary when Processa Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get PCSA alertsJames Neal is recorded as Board Member at Processa Pharmaceuticals, Inc. (PCSA) since January 1, 2022. The newest filing on record that lists James Neal as Board Member at Processa Pharmaceuticals, Inc. (PCSA) is dated June 18, 2026. Earlier roles on record: Board Member at XOMA Royalty Corp until January 1, 2023 and CEO at XOMA Royalty Corp until December 31, 2022. The proxy statement of XOMA Royalty Corp reports total compensation of $3,510,795 for James Neal in fiscal 2021, including a base salary of $593,166. Disclosed compensation is on record for 4 fiscal years. Processa Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Processa Pharmaceuticals, Inc. includes George Ng (CEO and Board Member), Russell L. Skibsted (CFO), Russell Skibsted (CFO) and 7 others.
2022-01-01–present
Last confirmed June 18, 2026
XOMA Royalty Corp
Board Member
Proxy statement
Start not stated–2023-01-01
XOMA Royalty Corp
CEO
Proxy statement
Start not stated–2022-12-31
Biotechnology · Healthcare
Board Member
2022-01-01–present
XOMA Royalty Corp
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | XOMA Royalty Corp | Former Chief Executive Officer | $593,166 | $3,510,795 |
| 2020 | XOMA Royalty Corp | Chief Executive Officer | $533,527 | $1,693,762 |
| 2019 | XOMA Royalty Corp | Chief Executive Officer | $498,623 | $1,479,559 |
| 2018 | XOMA Royalty Corp | Chief Executive Officer | $484,100 | $1,323,455 |
No call appearances or filed executive changes recorded yet.